International Stem Cell (ISCO) Licenses Open RAN IMC to Protect Mission-Critical 5G
- International Stem Cell offers licenses for its patented IMC software to harden mission‑critical 5G networks.
- IMC is Open RAN‑compatible and autonomously detects, identifies, and cancels real‑time RF interference and jamming.
- ISCO will demonstrate IMC at MWC 2026, highlighting continuous RAN operation preserving service continuity amid rising jamming threats.
International Stem Cell advances licensed software to protect 5G for critical services
International Stem Cell Corp (ISCO) is offering licensing for its patented Interference Management and Cancellation (IMC) software as it moves to position the technology as a defensive tool for mission‑critical 5G networks. The company says IMC is Open RAN‑compatible and autonomously detects, identifies and cancels a range of radio frequency interference and jamming threats in real time, aiming to harden public and private 5G deployments used by utilities, healthcare, transportation and first responders.
ISCO frames the licensing push as a strategic extension of its technology portfolio into communications resilience. CEO Gordon Reichard Jr. says IMC operates continuously within the radio access network to reduce outage durations, protect mission data flows and maintain service continuity under contested spectrum conditions. The software is designed for multivendor RAN architectures and can be integrated into O‑RAN radio units (O‑RUs) or distributed units (O‑DUs), which the company says allows operators to preserve performance and customer experience while lowering operational risk for critical infrastructure.
Industry analysts and stakeholders cite rising electromagnetic threats as driving urgent demand for such capability. Joe Madden, founder of Mobile Experts, says immunity to interference is increasingly important for private cellular networks serving utilities, transportation hubs and government applications. ISCO presents IMC as field‑proven autonomous software that streamlines access to interference management and cancellation capabilities for more robust, electronically hardened 5G communications.
Demonstration and market context
ISCO plans to demonstrate its Open RAN IMC technology at Mobile World Congress (MWC) 2026 in Barcelona, March 2‑5, giving attendees an opportunity to see the system in operational scenarios, the company says. The appearing at MWC positions the firm among vendors targeting operators and enterprises adopting O‑RAN architectures.
Security pressures underscore demand: ISCO notes that illegal jammers seized by U.S. law enforcement have risen by more than 800% in five years and have been used to block 911 calls during home invasions and bank robberies. The company says IMC’s autonomous monitoring and mitigation tools help maintain awareness and service continuity in contested spectrum, a capability it says is becoming essential as reliance on 5G for mission‑critical functions grows.
Related Cashu News

Travere Therapeutics Reports Positive FILSPARI Results and Achieves First Profitable Quarter
Travere Therapeutics (Ticker: TVTX) shows promising advancements in its drug FILSPARI, vital in treating focal segmental glomerulosclerosis (FSGS). Recently, the company released positive long-term da…

PTC Therapeutics Raises $500 Million for Debt Management and Growth in Biopharmaceuticals
PTC Therapeutics (Ticker: PTCT) aims to strengthen its financial position through a recent private placement of $500 million in Convertible Senior Notes due in 2031. This strategic move is intended to…

Insmed Navigates Investor Changes Amid Strong Pipeline and Mixed Analyst Sentiment
Insmed Inc (Ticker: INSM) is in a transformative phase as it navigates recent changes in its investor landscape and the impact on its business model. The company, known for its focus on rare diseases,…

Atossa Therapeutics Raises $4.5 Million to Support Oncology Clinical Development Efforts
Atossa Therapeutics (Ticker: ATOS) successfully finalizes a registered direct offering, generating approximately $4.5 million. This funding is crucial as the company progresses its clinical efforts ai…